Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.41 |
| ▸ | CDK4 | P11802 | 8/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
| ▸ | CDK7 | P50613 | 3/20 | 0.35 |
| ▸ | CDK9 | P50750 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | COMT | P21964 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403274 | 0.82 | CDK2 (0.34) | CDK2CDK4CCNE1AURKACDK9 | |
| SCHEMBL2347681 | 0.76 | TLR8 (0.43) | PLK1 | |
| SCHEMBL3574498 | 0.75 | CCR1 (0.43) | LMNA | |
| SCHEMBL591865 | 0.75 | DRD2 (0.44) | CDK4LMNAHTT | |
| SCHEMBL3572766 | 0.75 | TGFBR1 (0.37) | IDH1 | |
| SCHEMBL2351423 | 0.74 | TLR8 (0.44) | CDK4LMNAHTT | |
| SCHEMBL3571130 | 0.74 | TLR8 (0.46) | LMNAIDH1 | |
| SCHEMBL591990 | 0.73 | DRD2 (0.47) | CDK4 | |
| SCHEMBL2745920 | 0.72 | CYP2C9 (0.40) | COMT | |
| SCHEMBL2347045 | 0.72 | TLR8 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| EP-2007751-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, HTR3A | CDK2 647/4885CDK4 825/4885CCNE1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.